Journal of the American Society of Nephrology · 2006 · 175 citations · 9 references
MedicineNephrologyPharmacotherapyKidney TransplantationTransplant PharmacotherapyTransplant SurgeryHeart Transplant PharmacotherapyHeart TransplantationImmunosuppression In Kidney TransplantationTransplant OutcomesTransplant PharmacologyTransplant RejectionAngiotensin Ii Receptor BlockersHeart Transplant CareKidney Transplant CareKidney Transplant PharmacotherapyLong-term Graft FunctionLong-term Graft SurvivalRecipient Graft SurvivalRenin-angiotensin System Blockade
It was reported recently that treatment of kidney transplant recipients with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II type 1 receptor blockers (ARB) is associated with strikingly improved long-term graft and patient survival. This finding has important implications for future posttransplantation therapy recommendations. In an analysis of 17,209 kidney and 1744 heart transplant recipients, an association of treatment with ACEI/ARB with improved transplant outcome could not be confirmed. It is concluded that recommendations for a widespread use of ACEI/ARB treatment in transplant recipients are unwarranted.
9